DraftmedimpactPolicy N/A

P&T recommendations for Alyftrek and related CFTR modulators — coverage criteria summary

Customize your policy alerts

Sign up for all medimpact policy alerts

Know when medimpact releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Summarizes the P&T Advisory Committee recommendations (April 15, 2025) for Alyftrek and related CFTR modulators, including initial and renewal coverage criteria, documentation, age and quantity limits, and formulary placement; affects Medicaid pharmacy coverage pending state review.

Policy Summary

Payermedimpact

PolicyP&T recommendations for Alyftrek and related CFTR modulators — coverage criteria summary

Policy CodePolicy N/A

Change TypeAdded product-specific PA criteria and requirements

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prior authorization with documentation of diagnosis, FDA‑approved diagnostic/genotype confirmation, baseline predicted FEV1, and evidence of disease response for renewals.

SourceLink

POLICY UPDATE CHANGES

Multiple new products and their specific approval criteria were added (e.g., Ryzumvi, Journavx, Tryngolza, Hympavzi, Crinecerfont, Olezarsen).

Specific initial and renewal criteria including prescriber specialty, laboratory/genetic confirmation, and attestation requirements were added for several products.

Apr 15, 2025P&T meeting date

Non-PDLFormulary placement

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

DraftmedimpactPolicy N/A

P&T recommendations for Alyftrek and related CFTR modulators — coverage criteria summary

Customize your policy alerts

Sign up for all medimpact policy alerts

Know when medimpact releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payermedimpact

PolicyP&T recommendations for Alyftrek and related CFTR modulators — coverage criteria summary

Policy CodePolicy N/A

Change TypeAdded product-specific PA criteria and requirements

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prior authorization with documentation of diagnosis, FDA‑approved diagnostic/genotype confirmation, baseline predicted FEV1, and evidence of disease response for renewals.

SourceLink

POLICY UPDATE CHANGES

Multiple new products and their specific approval criteria were added (e.g., Ryzumvi, Journavx, Tryngolza, Hympavzi, Crinecerfont, Olezarsen).

Specific initial and renewal criteria including prescriber specialty, laboratory/genetic confirmation, and attestation requirements were added for several products.

Apr 15, 2025P&T meeting date

Non-PDLFormulary placement

Disease responseRenewal requirement

FEV1Baseline required

FDA testGenotype confirmation

Coverage Criteria (Initial & Renewal)

inv-03: Initial Approval

Covered when ALL of the following are met for initial approval

Initial Approval: Patient has a documented diagnosis of cystic fibrosis; a genetic profile (gene mutation) considered responsive to the product based on clinical and/or in vitro data in the FDA labeling; confirmation by an FDA-approved diagnostic test; patient meets the FDA-approved minimum age; documentation of baseline functional status and baseline predicted FEV1.

Repeated across multiple product entries

inv-02: Renewal Criteria

Renewal covered when ALL of the following are met (as present in excerpt):

Renewal: Patient has a documented diagnosis of cystic fibrosis with a genetic profile considered responsive per FDA labeling and confirmed by an FDA-approved diagnostic test; patient meets FDA-approved minimum age; documentation of baseline functional status and baseline predicted FEV1

inv-04: Renewal Criteria

Covered when ALL of the following are met for renewal

Renewal Approval: Patient continues to have documented CF diagnosis with responsive genotype confirmed by an FDA-approved diagnostic test; patient meets the FDA-approved minimum age; documentation of baseline functional status and baseline predicted FEV1; patient has had disease response as indicated by one or more measures (e.g., decreased pulmonary exacerbations compared to pre-treatment).

Disease response examples listed (decreased exacerbations)

inv-05: Renewal (Continuation) Criteria

Renewal is supported when ALL of the following are documented:

Renewal main criteria: Patient meets FDA-approved minimum age; AND documentation (e.g., progress notes) of baseline functional status and baseline predicted FEV1; AND evidence of disease response as indicated by one or more of the specified response measures; AND genetic profile considered responsive per FDA labeling confirmed by an FDA-approved diagnostic test.

Disease response can be one or more of decreased pulmonary exacerbations vs pre-treatment baseline OR improvement or stabilization of lung function vs baseline.

inv-06: Renewal Therapy

Renewal covered when ALL of the following are met

Renewal prerequisites: Confirmed diagnosis by an FDA-approved diagnostic test; patient meets the FDA-approved minimum age; documentation of baseline functional status and baseline predicted FEV1 provided

These three elements are required for renewal

Clinical response (one or more required): Disease response indicated by one or more: decreased pulmonary exacerbations compared to pre-treatment baseline; improvement or stabilization of lung function compared to baseline; decrease in decline of lung function; improvement in quality of life, weight gain, or growth>=1

At least one of these outcomes must be documented

inv-07: Initial and Renewal Criteria

Covered when ALL of the following are met

Initiation requirements: Patient meets the FDA-approved minimum age; Documentation (e.g., progress notes) of baseline functional status and baseline predicted FEV1.age >= FDA minimum

FDA minimum age referenced repeatedly in text

Renewal requirements: Patient has had disease response as indicated by one or more of: decreased pulmonary exacerbations vs pre-treatment baseline; improvement or stabilization of lung function vs baseline; decrease in decline of lung function; improvement in quality of life, weight gain, or growth.at least 1 response measure

Documentation of baseline functional status and baseline predicted FEV1 should be on file

inv-08: Initiation and Renewal

Covered when ALL of the following are met

Initiation criteria: Patient meets the FDA-approved minimum age (6 years) AND documentation (e.g., progress notes) of baseline functional status and baseline predicted FEV1 is provided.

Renewal criteria: Patient has demonstrated disease response as indicated by one or more of: decreased pulmonary exacerbations compared to pre-treatment baseline; improvement or stabilization of lung function compared to baseline; decrease in decline of lung function; or improvement in quality of life, weight gain, or growth; AND documentation of baseline functional status and baseline predicted FEV1 is on file.

inv-09: Renewal (Continuation) Criteria

Renewal covered when ANY of the following are met

Renewal disease response: Patient has had disease response indicated by one or more of: decreased pulmonary exacerbations compared to pre-treatment baseline; improvement or stabilization of lung function compared to baseline; decrease in decline of lung function; improvement in quality of life, weight gain, or growth.>=1 indicator

Used to justify renewal of therapy

inv-10: Age and Quantity Requirements

Coverage limits

Age and Quantity Limits: Patient is >= 6 years of age AND quantity limit for 50-20-4 mg tablets is 3 per day.age >=6; qty=3/day

Applies to referenced formulation

inv-11: Initial and renewal coverage criteria

Covered when ALL of the following are met

Age requirement: Patient is 6 years of age or older>= 6 years

Disease response requirement: Patient has had disease response as indicated by one or more of: decreased pulmonary exacerbations vs pre-treatment baseline; improvement or stabilization of lung function vs baseline; decrease in decline of lung function; or improvement in quality of life, weight gain, or growth.one_or_more

This single condition can be satisfied by any one of the listed responses

Quantity limits by strength: Adhere to specified quantity limits for tablet strengths: 50-20-4 mg tablets = 3 per day; 125-50-10 mg tablets = 2 per day.exact

Multiple permutations and repeated entries in source consistently state these daily limits

inv-12: Renewal (Continuation) Criteria

Covered when ALL of the following are met for renewal:

Renewal general

Disease response criteria: One or more of: decreased pulmonary exacerbations compared to pre-treatment baseline; improvement or stabilization of lung function compared to baseline; decreased rate of lung function decline; or improvement in quality of life, weight gain, or growth.
Any single item sufficient

inv-13: Renewal / Continued Coverage

Covered with criteria — renewal requires ALL of the following be documented as applicable:

Renewal requirements

Disease response (any one): Patient has had disease response as indicated by one or more of: decreased pulmonary exacerbations compared to pre-treatment baseline; OR improvement or stabilization of lung function compared to baseline; OR decrease in decline of lung function; OR improvement in quality of life, weight gain, or growth
Documentation should compare to pre-treatment baseline

inv-14: Initial and continuation therapy criteria

Covered when ALL of the following are met:

Eligibility and limits: Patient is at least 6 years of age; requested quantity does not exceed product-specific daily limits (50-20-4 mg tablets: 3 per day; 125-50-10 mg tablets: 2 per day).age >= 6 years; quantity <= stated limits

Exact tablet strengths and per-day maxima listed in document.

Demonstrated disease response: Patient has had disease response, indicated by one or more of: decreased pulmonary exacerbations compared to pre-treatment baseline; improvement or stabilization of lung function compared to baseline; decrease in decline of lung function; or improvement in quality of life, weight gain, or growth.>=1 response criterion

Documentation of at least one of these outcomes required for continuation.

inv-15: Initial Therapy - Sofpironium

Sofpironium (Ryzumvi) — Covered when ALL of the following are met

Sofpironium initial criteria: Patient has a diagnosis of primary axillary hyperhidrosis; AND Prescriber attests hyperhidrosis is significantly interfering with activities of daily living; AND Patient meets the FDA-approved minimum age.

Approval duration: 6 months; Age limit: 9 years or older; Quantity limit: 1 bottle per 30 days

inv-16: Approval Criteria - Phentolamine

Phentolamine — Covered when ALL of the following are met

Phentolamine approval criteria: Patient has pharmacologically-induced mydriasis produced by adrenergic agonists or parasympatholytic agents; AND Prescriber attests product will be used within 24 hours of the procedure; AND Prescribed by, or in consultation with, an ophthalmologist or other specialist in the treatment of pharmacologically-induced mydriasis.

Approval: Single fill only; Age limit: 3 years or older; Quantity limit: 1 single-patient-use vial per fill

inv-17: Initial and Renewal Criteria - Crenessity (crinecerfont)

Crenessity — Covered when ALL of the following are met

Crenessity initial criteria: Patient has a diagnosis of classic congenital adrenal hyperplasia (CAH) defined by ≥1 of: elevated 17-hydroxyprogesterone (17-OHP) OR confirmed CYP21A2 genotype OR positive newborn screening with confirmatory second-tier testing OR cosyntropin stimulation test; AND Prescribed initially by, or in consultation with, an endocrinologist; AND Crenessity will be used as adjunct therapy with chronic glucocorticoid therapy at a minimum glucocorticoid replacement dose; AND If prescribed with a moderate or strong CYP3A4 inducer, dosages will be modified per package insert; AND Patient meets package insert minimum age.

Initial approval: 6 months; renewal: 1 year with evidence of improvement (e.g., reduction in glucocorticoid daily use or reduction in serum androstenedione)

inv-18: Initial Criteria - Journavx (suzetrigine)

Journavx — Covered when ALL of the following are met

Journavx initial criteria: Patient has a diagnosis of moderate to severe acute pain; AND Journavx will be used for up to 14 days; AND Prescriber attests pain is unable to be managed with an NSAID, acetaminophen, or other non-opioid analgesic; AND Not being prescribed for chronic pain or migraine-related pain; AND Patient does not have severe hepatic impairment (Child-Pugh C); AND Counseling provided regarding grapefruit avoidance; AND Not taking a strong CYP3A inhibitor or a moderate/strong CYP3A inducer; AND Counseling on contraceptive interactions provided if applicable; AND Patient meets package insert minimum age.

Approval duration: 3 months (limit 1 fill per approval); Age limit: 18 years or older; Quantity limit: 30 tablets per 14 days

inv-19: Initial and Renewal Criteria - Olezarsen / Tryngolza

Tryngolza — Covered when ALL of the following are met

Olezarsen initial criteria: Diagnosis of familial chylomicronemia syndrome confirmed by pathogenic mutations in LPL, APOA5, GPIHBP1, LMF1, or APOC2; AND Fasting triglyceride ≥ 880 mg/dL; AND Patient will follow a low-fat diet (≤20 g fat/day); AND Prescribed by or in consultation with an endocrinologist or other FCS specialist; AND Patient meets package insert minimum age.

Approval duration: 1 year; Renewal requires prescriber attestation of clinically significant improvement or stabilization; Age limit: 18 years or older; Quantity limit: 1 autoinjector per month

inv-20: Initial Criteria - Hympavzi

Hympavzi — Covered when ALL of the following are met

Hympavzi initial criteria: Prescribed for prophylactic treatment in patients with hemophilia A without inhibitors to Factor VIII OR hemophilia B without inhibitors to Factor IX; AND Documentation (e.g., inhibitor lab result within past year) demonstrating absence of Factor VIII or Factor IX inhibitors; AND Patient meets package insert minimum age.

Approval duration: 1 year initial and renewal

inv-21: Initial Therapy — No Inhibitors

Covered when ALL of the following are met:

Initial Approval Criteria (no inhibitors): Prescribed for prophylactic treatment in patients with hemophilia A without FVIII inhibitors OR hemophilia B without FIX inhibitors; documentation (e.g., inhibitor lab result within the past year) demonstrating absence of Factor VIII inhibitors for hemophilia A OR absence of Factor IX inhibitors for hemophilia B; patient meets the minimum age recommended by the package insert for the provided indication.

inv-22: Renewal — No Inhibitors

Covered on renewal when ALL of the following are met:

Renewal Criteria (no inhibitors): Prescriber attests patient has experienced clinical benefit compared to baseline; documentation (e.g., inhibitor lab result within the past year) demonstrating absence of Factor VIII inhibitors for hemophilia A OR absence of Factor IX inhibitors for hemophilia B.

Approval duration: 1 year

inv-23: Initial Therapy — With Inhibitors

Covered when ALL of the following are met:

Initial Approval Criteria (with inhibitors): Prescribed for prophylactic treatment in patients with hemophilia A with FVIII inhibitors OR hemophilia B with FIX inhibitors; documentation (e.g., inhibitor lab result within the past year) demonstrating presence of Factor VIII inhibitor for hemophilia A OR presence of Factor IX inhibitor for hemophilia B; patient meets the minimum age recommended by the package insert for the provided indication.

inv-24: Renewal — With Inhibitors

Covered on renewal when ALL of the following are met:

Renewal Criteria (with inhibitors): Prescriber attests patient has experienced clinical benefit compared to baseline; documentation (e.g., inhibitor lab result within the past year) demonstrating presence of Factor VIII inhibitor for hemophilia A OR presence of Factor IX inhibitor for hemophilia B.

Approval duration: 1 year

No explicit exclusions are listed in the provided excerpt.

No explicit exclusions are listed in the provided text.

No explicit exclusions are stated in these chunks.

No explicit exclusions are stated in this section.

No explicit exclusions stated in this excerpt.

No explicit exclusions are listed in this section.

Patients younger than 6 years of age are outside the stated age limit and therefore excluded from coverage per the age restriction noted in the recommendations.

None explicitly stated in this section.

None specified in this section.

Journavx (suzetrigine) is explicitly excluded for use in chronic pain and for pain associated with migraine per the product-specific approval criteria.

Per the Alhemo renewal criteria, patients under 12 years of age do not meet the stated age limit.

Conditions rendering therapy not medically necessary are not specified in this excerpt.

No explicit 'not medically necessary' conditions appear in the provided text.

While the document does not list explicit 'not medically necessary' conditions, lack of required documentation or absence of demonstrated disease response is implied as grounds to not continue coverage.

Not specified in this excerpt; failure to meet renewal prerequisites or demonstrate clinical response would imply lack of medical necessity.

Renewal would be considered not medically necessary if there is no documented disease response as defined in the renewal criteria (one or more specified clinical improvements) or if baseline documentation is not provided.

Requests for renewal that lack evidence of disease response as defined (for example, decreased pulmonary exacerbations, improved or stabilized lung function, decreased decline in lung function, or improvements in quality of life/weight/growth) may be considered not medically necessary.

Not explicitly stated; however, absence of documented disease response per the renewal definitions would not meet medical necessity for continued coverage.

Not explicitly defined in this section; lack of documented disease response would imply the therapy is not medically necessary on renewal.

The document does not list specific 'not medically necessary' conditions; however, failure to demonstrate disease response or exceeding stated age or quantity limits would imply denial of continued coverage.

Provider Requirements, Documentation & Denial Triggers

Prior Authorization

Prior authorization required; 6‑month approvals

Alyftrek was recommended Non‑PDL and requires prior authorization; approvals are issued for 6 months per the P&T recommendation.

Prior Authorization

Initial authorization: diagnosis, genotype, age, baseline FEV1

Initial prior authorization requires a documented diagnosis of cystic fibrosis with a genetic profile considered responsive per FDA labeling, confirmation by an FDA‑approved diagnostic test, patient meeting the FDA‑approved minimum age, and documentation (e.g., progress notes) of baseline functional status including baseline predicted FEV1.

Prior Authorization

Renewal: age and genotype confirmation required

Renewal requests must document that the patient meets the FDA‑approved minimum age and that the responsive genetic profile remains confirmed by an FDA‑approved diagnostic test, and baseline function documentation is on file.

Formulations, Dosing & Coding

Baseline predicted FEV1 — documentation

RequirementDocumentation (e.g., progress notes) of baseline predicted FEV1 is required prior to initiation of therapy.

Threshold detailNo numeric baseline predicted FEV1 threshold is specified in the excerpt; the policy requires the value be documented.

When requiredBaseline predicted FEV1 must be provided at initiation and is expected to be on file for renewals.

Minimum age

RequirementPatient must meet the FDA‑approved minimum age for the product indication.

DocumentationProvider must confirm age meets package‑insert (FDA) minimum age as part of prior authorization.

Key Definitions

CFTR activity

DefinitionCFTR activity = activity of the cystic fibrosis transmembrane conductance regulator protein at the cell surface; increased by combination CFTR modulators.

Mechanistic noteVanzacaftor and tezacaftor increase CFTR amount on the cell surface; deutivacaftor increases channel open probability—together they increase CFTR activity.

Clinical relevancePolicy requires a genetically responsive profile and diagnostic confirmation for drugs that increase CFTR activity.

Responsive genetic profile

DefinitionA responsive genetic profile is a CF gene mutation considered responsive to the product based on clinical and/or in vitro data in the FDA labeling.

RequirementResponsive genotype must be documented for initial approval and confirmed by an FDA‑approved diagnostic test.

Background & Scope

Alyftrek is a combination CFTR modulator therapy intended to increase CFTR protein activity at the cell surface; components work additively to increase CFTR amount and channel open probability. The P&T recommendation designates Alyftrek as Non-PDL with an approval duration of 6 months and requires prior authorization consistent with the committee recommendations.

Policy Revision History

2025-04-15policy_additionsLatest

Multiple new products (including Ryzumvi/sofpironium, Crenessity/crinecerfont, Journavx/suzetrigine, Tryngolza/olezarsen, Hympavzi) and their product-specific prior authorization criteria, approval durations, age/quantity limits, and specialty prescriber requirements were added to the policy.

2025-04-15operational_requirementLatest

Prior authorization reviewers must verify product-specific requirements at initial and renewal authorization, including specialist prescribing/consultation, laboratory or genetic confirmation (e.g., genetic mutations, elevated 17‑OHP, inhibitor lab results), and required prescriber attestations per product.

Policy Summary

Payermedimpact

PolicyP&T recommendations for Alyftrek and related CFTR modulators — coverage criteria summary

Policy CodePolicy N/A

Change TypeAdded product-specific PA criteria and requirements

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prior authorization with documentation of diagnosis, FDA‑approved diagnostic/genotype confirmation, baseline predicted FEV1, and evidence of disease response for renewals.

SourceLink

On This Page

Prior Authorization

Renewal: document disease response (≥1 measure)

Prior authorization renewal requires evidence of disease response since initiation, defined by one or more of the listed clinical improvements (e.g., decreased pulmonary exacerbations vs pre‑treatment baseline; improvement or stabilization of lung function; decreased decline in lung function; or improvement in quality of life, weight gain, or growth).

Documentation Required

Baseline functional status and age must be documented

Prior authorization requires documentation of baseline functional status and baseline predicted FEV1 at initiation, and that the patient meets the FDA‑approved minimum age.

Prior Authorization

PA and renewal: baseline FEV1 and FDA age requirement

Both initial prior authorization and renewals require documentation of baseline functional status and baseline predicted FEV1 and confirmation that the patient meets the FDA‑approved minimum age.

Prior Authorization

Renewal: response evidence required; quantity limits apply

Renewal authorizations require evidence of disease response as shown by one or more specified clinical improvements (see renewal criteria); quantity limits apply per tablet strength (e.g., 50‑20‑4 mg tablets: 3 per day).

Evidence of ≥1 response measure required for renewal
Adhere to product-specific quantity limits (50‑20‑4 mg = 3/day)

Prior Authorization

Age ≥6 years and documented response required

Prior authorization requires documentation that the patient is at least 6 years of age and has had disease response as defined in the renewal criteria.

Prior Authorization

PA implied by quantity/renewal criteria; age and response required

Initial and renewal approvals both require evidence of age and disease response per the criteria; the presence of quantity limits and renewal criteria implies prior authorization is required.

Prior Authorization

PA/renewal: document response and follow quantity limits

Prior authorization and renewals require documentation of disease response (per renewal criteria) and that prescribed quantities adhere to the stated product‑specific limits.

Document disease response using one or more renewal measures
Ensure requested quantity does not exceed daily tablet limits

Prior Authorization

6‑month approval duration; response required at renewal

Prior authorization is required per the recommendation; approvals are issued for 6 months and renewals must include documentation of clinical response to justify continuation.

Prior Authorization

PA: follow product‑specific initial criteria (diagnosis, attestation, labs)

Prior authorization requires product‑specific initial criteria including diagnosis confirmation, prescriber attestations or specialist prescription/consultation as specified, laboratory/genotype evidence, and adherence to age and quantity limits.

Follow prescriber attestation or specialist requirement when indicated
Provide lab/genotype evidence per product entry

Documentation Required

Provide inhibitor lab result and meet package‑insert indications

For indications that differentiate inhibitor status, prior authorization requires documentation of inhibitor lab results (within the past year) showing either absence or presence as appropriate and that the patient meets package‑insert indications.

Include an inhibitor lab result within the past year
Attest to clinical benefit on renewal when required

Step Therapy

No step therapy sequences specified

No explicit step therapy sequences are specified in the provided sections of this document.

Step Therapy

No step therapy sequencing stated

The document does not define a step therapy sequencing requirement for Alyftrek or related CFTR recommendations in the provided text.

Step Therapy

Journavx: prescriber attestation of failure of non‑opioid analgesics

For Journavx (suzetrigine) specifically, prescriber must attest that the member's acute pain cannot be managed with an NSAID, acetaminophen, or other non‑opioid analgesic prior to approval.

Journavx is limited to up to 14 days and excludes chronic pain and migraine‑related pain

Documentation Required

Document baseline functional status and predicted FEV1 (progress notes)

Progress notes documenting baseline functional status and baseline predicted FEV1 are required at initiation and must be available for review.

Documentation Required

Progress notes required at initiation and to show response at renewal

Required documentation at initiation includes progress notes of baseline functional status and baseline predicted FEV1; at renewal, documentation demonstrating disease response (per renewal criteria) must be provided.

Baseline progress notes at initiation
Follow‑up documentation showing clinical benefit for renewal

Documentation Required

Provide FDA‑approved diagnostic test confirming genotype

Documentation must include confirmation of genotype by an FDA‑approved diagnostic test to verify the patient has a CF gene mutation considered responsive to the product per FDA labeling.

Documentation Required

Submit progress notes with baseline FEV1

Provide progress notes documenting baseline functional status and baseline predicted FEV1 as part of required baseline documentation.

Documentation Required

Initiation: baseline FEV1 plus FDA genotype confirmation

At initiation submit documentation (e.g., progress notes) of baseline functional status and baseline predicted FEV1 and include evidence of genotype confirmation by an FDA‑approved diagnostic test.

Documentation Required

Baseline progress notes required at initiation and expected at renewal

Submit progress notes documenting baseline functional status and baseline predicted FEV1 at initiation; the same documentation is expected for renewal to support continued coverage.

Documentation Required

Renewal must show disease response vs pre‑treatment baseline

Renewal documentation must demonstrate disease response since initiation using one or more of the specified measures (decreased pulmonary exacerbations vs pre‑treatment baseline; improvement/stabilization of lung function; decreased decline of lung function; or improved quality of life, weight gain, or growth).

Documentation Required

Include baseline and follow‑up clinical measures showing response

Clinical documentation supporting renewal should include baseline and follow‑up measures (examples: pulmonary exacerbation frequency, FEV1, weight/growth, quality‑of‑life measures) demonstrating disease response.

Compare follow‑up measures to pre‑treatment baseline
Examples: exacerbation frequency, FEV1, weight or growth, QoL measures

Documentation Required

Documentation: age, formulation/quantity, and response checklist

Documentation checklist should support patient age (≥6 years), the prescribed tablet formulation and daily quantity, and evidence of disease response compared to baseline.

Confirm age ≥6 years
Specify tablet formulation and daily quantity requested
Provide evidence of disease response vs baseline

Documentation Required

Required documentation of response: one or more listed outcomes

Documentation must show patient has had disease response compared to pre‑treatment baseline, demonstrated by one or more of the listed outcomes (decreased pulmonary exacerbations; improved/stable FEV1 or decreased decline; improved quality of life, weight gain, or growth).

Documentation Required

Provide product‑specific diagnostic confirmation examples when applicable

Required supporting documentation examples vary by product and include diagnostic confirmation (e.g., elevated 17‑OHP, confirmed CYP21A2 genotype, positive newborn screen with confirmatory testing) as specified in the product entries.

Documentation Required

Inhibitor lab within 1 year and prescriber attestation at renewal

Documentation must include an inhibitor lab result within the past year demonstrating absence (for non‑inhibitor indications) or presence (for inhibitor indications) of factor inhibitors, plus prescriber attestation of clinical benefit at renewal where required.

Denial Risk

Denial risk: missing genotype confirmation

Failure to document a genetic profile considered responsive per FDA labeling or failure to confirm the genotype by an FDA‑approved diagnostic test may result in denial of prior authorization.

Denial Risk

Denial risk: unconfirmed responsive gene mutation

Lack of documentation that a gene mutation is considered responsive to the product based on FDA labeling, or absence of confirmation by an FDA‑approved diagnostic test, may trigger denial.

Denial Risk

Denial risk: missing baseline functional status/FEV1

Failure to provide documentation of baseline functional status and baseline predicted FEV1 may trigger denial of the initial prior authorization or renewal.

Denial Risk

Denial risk on renewal for missing baseline data

Missing baseline functional status and baseline predicted FEV1 on file may lead to denial of renewal requests.

Denial Risk

Denial trigger: missing baseline or FDA diagnostic confirmation

Lack of required documentation (baseline functional status and baseline predicted FEV1) or failure to confirm diagnosis with an FDA‑approved test may trigger denial of a request.

Denial Risk

Denial risk: no baseline or no demonstrated response at renewal

Absence of documented baseline functional status/FEV1 or lack of evidence of disease response on renewal may trigger denial.

Denial Risk

Denial risk: missing initiation documentation

Failure to document baseline functional status and baseline predicted FEV1 at initiation may risk denial of renewal or prior authorization requests.

Denial Risk

Denial trigger: insufficient evidence of disease response

Lack of documented disease response as defined in the renewal criteria may trigger denial of renewal requests.

Denial Risk

Denial triggers: failure to meet explicit criteria

Requests that do not meet the explicit renewal or initial criteria for documented disease response (see documentation requirements) may be denied.

Denial Risk

Denial risk: patient below minimum age (≥6 years required)

Requests for therapy for patients younger than the stated minimum (e.g., under 6 years of age) would not meet the age limit and risk denial.

Denial Risk

Denial risk: exceeding quantity or age limits

Requests exceeding the stated quantity limits for a product or for patients under the age limit may be denied.

Denial Risk

Denial triggers: age/quantity exceedance or missing response

Requests exceeding age or quantity limits, or lacking documentation of disease response per renewal criteria, may be denied.

Denial Risk

Denial triggers: missing diagnosis confirmation, specialty consults, or labs

Denial may be triggered if the patient lacks specified diagnostic confirmation, if prescriber specialty/consultation or attestation requirements are not met, or if required laboratory/genotype evidence is missing.

Provide prescriber attestation or specialist consultation when required
Include required lab/genotype evidence

Denial Risk

Denial risk: missing inhibitor status documentation

Lack of documentation demonstrating absence of factor VIII or IX inhibitors (for non‑inhibitor indications) or lack of documentation demonstrating presence (for inhibitor indications) may result in denial.

Note

Provider actions to prevent denials: submit complete documentation

General provider action: ensure all required documentation (diagnosis, genotype confirmation, baseline progress notes including predicted FEV1, age verification, quantity requested, and evidence of response at renewal) is submitted with PA requests to reduce risk of denial.

Include FDA‑approved diagnostic test results confirming genotype
Attach progress notes with baseline predicted FEV1
State patient age and requested tablet formulation/quantity
Provide follow‑up measures to demonstrate response at renewal

ApplicationAge requirement applies at initiation and is verified again for renewal requests.

Baseline spirometry

Required recordProgress notes documenting baseline functional status and baseline predicted FEV1 must be submitted.

PurposeBaseline spirometry (predicted FEV1) is used to compare for evidence of disease response on renewal.

TimingBaseline spirometry should be documented prior to treatment initiation and retained for renewals.

Baseline predicted FEV1 — requirement

Documentation requiredA documented baseline predicted FEV1 is required; the document does not specify a numeric cutoff.

Use at renewalBaseline predicted FEV1 is referenced as the comparator for demonstrating disease response on renewal.

FormAcceptable evidence is progress notes recording baseline functional status and predicted FEV1.

Age limit

Age limit>= 6 years of age

Applies toSpecified for product tablet formulations referenced in the policy (applies at initiation and renewal).

VerificationProvider must document patient age meets this limit as part of prior authorization submission.

Minimum patient age

Minimum patient age6 years of age or older

Policy roleAge requirement must be met for initial approval and is reiterated for renewals.

DocumentationProvider documentation should support the patient’s age (e.g., chart demographic data).

Quantity limit — 50-20-4 mg tablets

Daily limit50-20-4 mg tablets: 3 per day

ApplicationQuantity limit applies to the referenced tablet formulation for both initiation and renewal approvals.

VerificationPrior authorization reviewers must ensure requested quantity does not exceed the stated per‑day limit.

Age limit (repeated)

Age limit>= 6 years

ScopeStated consistently for tablet formulations in the policy; applies at initiation and renewal.

ConsequenceRequests for patients younger than the age limit risk denial per policy guidance.

Denial riskLack of documentation of a responsive mutation or lack of FDA test confirmation may trigger denial.

FDA‑approved diagnostic test

DefinitionFDA‑approved diagnostic test = a diagnostic test authorized by the FDA used to confirm the patient’s CFTR genotype.

Policy useConfirmation by an FDA‑approved diagnostic test is required for initial approval and renewal verification.

DocumentationProviders must submit evidence of the FDA‑approved test result as part of prior authorization documentation.

Disease response — definition

DefinitionDisease response = one or more of: decreased pulmonary exacerbations; improvement or stabilization of lung function; decreased decline in lung function; or improvement in quality of life, weight, or growth.

Use for renewalAt renewal, documentation must show one or more of these outcomes compared to pre‑treatment baseline.

ExamplesExamples include fewer pulmonary exacerbations versus baseline or stabilized/improved FEV1 measurements.

Genetic profile confirmation

DefinitionGenetic profile confirmation = a gene mutation considered responsive per FDA labeling and confirmed by an FDA‑approved diagnostic test.

Policy roleRequired for initial approval and reiterated as a renewal prerequisite in the policy.

DocumentationProvider must supply FDA‑approved diagnostic test results to confirm the responsive mutation.

Disease response — alternate phrasing

DefinitionDisease response (alternate wording) = one or more of: decreased pulmonary exacerbations; improvement or stabilization of lung function; improved weight/growth; improved quality of life.

Renewal evidencePolicy allows any single listed response measure to satisfy the renewal clinical‑benefit requirement.

Documentation examplesProgress notes, exacerbation frequency, and spirometry comparisons to baseline serve as supporting evidence.

Baseline documentation

Required baseline documentationProgress notes documenting baseline functional status and baseline predicted FEV1 prior to treatment must be submitted at initiation.

PurposeThese baseline records are used to assess clinical response at renewal.

RetentionBaseline documentation should remain on file and be available for prior authorization/renewal review.

Disease response — renewal measures

Disease response — renewalOne or more of: decreased pulmonary exacerbations; improvement or stabilization of lung function; improved weight/growth; improved quality of life — any single item can support renewal.

Documentation neededProvider must document the specific clinical improvement compared to pre‑treatment baseline.

ExamplesFrequency of exacerbations, spirometry trends, weight/growth charts, and QoL assessments may be used.

Baseline documentation — provider requirement

Baseline documentation requiredProgress notes documenting baseline functional status and baseline predicted FEV1 prior to treatment are required and must be provided with PA requests.

Renewal expectationSame baseline documentation is expected to remain on file for renewal and to compare outcomes.

Policy noteFailure to provide baseline documentation may result in denial of renewal or prior authorization.

Disease response — positive treatment effect

Disease response (summary)Positive treatment effect indicated by one or more: decreased pulmonary exacerbations; improvement or stabilization of lung function; decreased decline in lung function; or improvement in quality of life, weight gain, or growth.

Use for decisionsEvidence of any one of these outcomes supports renewal of therapy per policy.

Documentation standardComparisons should be made to pre‑treatment baseline using charted data.

Disease response — evidence for renewal

Disease response (evidence)Evidence of clinical benefit demonstrated by one or more of: decreased pulmonary exacerbations; improvement or stabilization of lung function; decreased decline of lung function; or improvement in quality of life, weight, or growth.

Policy implicationThis evidence is required for renewal to demonstrate continued medical necessity.

Examples of measuresExacerbation rates, FEV1 trends, and weight/growth improvements are commonly cited metrics.

Disease response — consolidated

Disease response (repeated)One or more of: decreased pulmonary exacerbations; improvement/stabilization of lung function; decreased rate of lung function decline; or improvement in quality of life, weight, or growth — any single item suffices for renewal.

Quantity and age contextRenewal requirements are combined with age (≥6 years) and quantity limits for tablet formulations.

Documentation guidanceProvide baseline and follow‑up clinical measures to show the change versus pre‑treatment baseline.

Mechanism of action — Sofpironium

Mechanism of actionSofpironium competitively inhibits acetylcholine receptors on some peripheral tissues, including sweat glands, decreasing the rate of sweating.

ContextProvided as the MOA statement for Ryzumvi in the recommendations section.

NoteMOA summaries for other new products are presented elsewhere in the document.

Mechanism summaries

PurposeConcise mechanism‑of‑action summaries are provided for each new product in the recommendations (e.g., CFTR modulators, NaV1.8 blocker, ASO, TFPI antagonist).

ExamplesExamples in the document include CFTR modulators increasing CFTR activity, suzetrigine blocking NaV1.8, and olezarsen acting on APOC‑III.

UsefulnessThese summaries inform reviewers of therapeutic class and expected physiologic effects relevant to coverage decisions.

Alhemo — mechanistic note

Alhemo descriptionAlhemo is a non‑factor, monoclonal antibody targeting and blocking tissue factor pathway inhibitor (TFPI); described as the only TFPI antagonist for use in patients WITH inhibitors.

Indication contextListed among new products with specified age and quantity limits and a 1‑year approval duration.

Documentation notePolicy distinguishes Alhemo as indicated for patients WITH inhibitors versus Hympavzi for those without inhibitors.

Inhibitor lab result

Inhibitor lab requirementAn inhibitor lab result within the past year demonstrating presence or absence of Factor VIII or IX inhibitors is required where applicable.

ApplicationRequired for initial approval (to document absence or presence) and for renewal (to confirm ongoing status) for hemophilia therapies.

ConsequenceFailure to provide an appropriate inhibitor lab result may trigger denial of the request.